🧬 EGFR Cancer Research

EGFR, or epidermal growth factor receptor, is a protein found on the surface of cells that plays a crucial role in cell growth and division. In cancer research, EGFR has emerged as one of the most important targets for developing precision therapies, particularly in lung cancer treatment. When cancer cells produce abnormal amounts of EGFR or develop mutations in the EGFR gene, these receptors can drive uncontrolled cell growth, making EGFR an ideal target for therapeutic intervention.

Over the past two decades, EGFR has revolutionized cancer care through the development of targeted therapies known as tyrosine kinase inhibitors (TKIs). These drugs are designed to specifically block EGFR signaling in cancer cells while minimizing damage to healthy tissue. For patients with EGFR-mutated lung cancers, these targeted therapies have significantly improved survival rates and quality of life compared to traditional chemotherapy. Beyond treatment, EGFR testing has become a critical diagnostic biomarker that helps oncologists identify which patients are most likely to benefit from specific targeted drugs, enabling truly personalized medicine approaches.

Current research continues to advance our understanding of EGFR biology, resistance mechanisms, and combination treatment strategies. This page features the latest peer-reviewed research on EGFR as a biomarker and diagnostic tool in cancer medicine, helping patients, caregivers, and healthcare providers stay informed about emerging discoveries and clinical applications.